Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29625352 | 0.80 | SIGMAR1 (0.43) | MAPTKMT2AHSD17B3MAOAMAOB | |
| SCHEMBL4854732 | 0.80 | SIGMAR1 (0.43) | MAPTKMT2AHSD17B3MAOAMAOB | |
| SCHEMBL1097697 | 0.78 | UTS2R (0.39) | MAPTUTS2R | |
| SCHEMBL22419911 | 0.75 | L3MBTL1 (0.35) | — | |
| SCHEMBL30869312 | 0.73 | HTR2A (0.41) | HTR2A | |
| SCHEMBL2619379 | 0.73 | HTR2A (0.41) | HTR2A | |
| SCHEMBL18199062 | 0.72 | KMT2A (0.34) | MAPTKMT2AMAOA | |
| SCHEMBL12191290 | 0.71 | HTR1A (0.37) | KMT2AMAOB | |
| SCHEMBL18536429 | 0.70 | HTR2A (0.38) | HTR2A | |
| SCHEMBL10626234 | 0.70 | MEN1 (0.31) | KMT2AHTR2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210226253-A1 | ELECTROLYTIC SOLUTION FOR LITHIUM-ION SECONDARY BATTERY, AND LITHIUM-ION SECONDARY BATTERY | MURATA MANUFACTURING CO., LTD. (JP) | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210226253-A1 | ELECTROLYTIC SOLUTION FOR LITHIUM-ION SECONDARY BATTERY, AND LITHIUM-ION SECONDARY BATTERY | TPO, DNASE1, KCNN2 | MAPT 2286/4885KMT2A 1116/4885HTR2A 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.